-
The company successfully commissioned an expanded manufacturing facility, increasing NexoBrid production capacity sixfold to meet anticipated global demand.
-
Revenue for 2025 was impacted by the U.S. government shutdown, which delayed budget approvals and the initiation of new development service contracts.
-
The Phase III VALUE trial for EscharEx in venous leg ulcers (VLU) is advancing as planned, with the majority of clinical sites now active and enrolling.
-
Strategic expansion of the EscharEx program into diabetic foot ulcers (DFU) and pressure ulcers aims to capture the three major chronic wound indications.
-
Gross margin improvement in 2025 was driven by a more favorable revenue mix despite lower overall top-line results.
-
Management maintains operational resilience and discipline in Israel despite ongoing regional conflict, ensuring clinical and commercial milestones remain on track.
-
Industry validation continues to grow through research collaborations with seven market-leading wound care companies, including a new partnership with B. Braun.
-
Revenue guidance of $24 million to $26 million for 2026 assumes regulatory approval of the expanded manufacturing facility and resumed BARDA/DOW support.
-
The 2028 revenue target of $50 million to $55 million includes the first potential commercial contributions from EscharEx, subject to regulatory approval.
-
Management expects to complete the EscharEx Phase III VALUE trial enrollment and conduct a prespecified interim assessment by year-end 2026.
-
Future growth strategy prioritizes national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems.
-
The company plans to initiate a Phase II study in diabetic foot ulcers and an investigator-initiated study in pressure ulcers during 2026.
-
The U.S. government shutdown served as a primary headwind in 2025, causing a $7.0 million revenue shortfall compared to initial expectations.
-
A $30.0 million registered direct offering and warrant exercises strengthened the balance sheet to $53.6 million in cash at year-end.
-
R&D expenses increased significantly to $14.0 million in 2025, reflecting the intensified investment required for the EscharEx Phase III program.
-
Commercial release of product from the new manufacturing site is contingent upon regulatory approvals expected in 2026.
-
Capacity has increased sixfold, but commercial output from the new site is subject to regulatory approvals expected in late 2026.
-
Management noted that current demand across territories exceeds current manufacturing capabilities, though they have guided conservatively based on expected clearance timelines.
